<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drug and alcohol dependence</journal-title></journal-title-group><issn pub-type="ppub">0376-8716</issn><issn pub-type="epub">1879-0046</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10332434</article-id><article-id pub-id-type="pmcid-ver">PMC10332434.319</article-id><article-id pub-id-type="pmcaid">10332434</article-id><article-id pub-id-type="pmcaiid">10332434</article-id><article-id pub-id-type="manuscript-id">NIHMS1909896</article-id><article-id pub-id-type="pmid">37301069</article-id><article-id pub-id-type="doi">10.1016/j.drugalcdep.2023.109952</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1909896</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1909896</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Trends in Overdose Deaths involving Gabapentinoids and Z-Drugs in the United States</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Powell</surname><given-names initials="D">David</given-names></name><degrees>Ph.D</degrees><aff id="A1">RAND, 1200 S. Hayes St., Arlington, VA 22202</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shetty</surname><given-names initials="KD">Kanaka D.</given-names></name><degrees>MD, MS</degrees><aff id="A2">RAND, 1776 Main St., Santa Monica, CA 90407</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peet</surname><given-names initials="ED">Evan D.</given-names></name><degrees>Ph.D</degrees><aff id="A3">RAND, 4570 Fifth Ave., Pittsburgh, PA 15213</aff></contrib></contrib-group><author-notes><corresp id="CR1">Corresponding author: David Powell, Ph.D, RAND, 1200 S. Hayes St., Arlington, VA 22202, <email>dpowell@rand.org</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P31"><bold>Declarations of Interest:</bold> The authors report grant funding from the National Institutes of Health and no other potential conflicts of interest.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>8</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>01</day><month>6</month><year>2023</year></pub-date><volume>249</volume><issue-id pub-id-type="pmc-issue-id">440315</issue-id><fpage>109952</fpage><lpage>109952</lpage><pub-history><event event-type="nihms-submitted"><date><day>23</day><month>06</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-20 22:25:47.137"><day>20</day><month>09</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1909896.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction:</title><p id="P1">As policies have been implemented to limit access to prescription opioids, other drugs have been prescribed off-label, sometimes concurrently with opioids, to manage pain. There are concerns about the use of gabapentinoids and &#8220;Z-drugs&#8221; with opioids. As the opioid crisis transitions to illicit opioids and polysubstance use, little work quantifies the concurrent involvement of non-opioid prescription drugs and illicit opioids in overdose deaths.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">Data from the census of deaths in the United States for 1999&#8211;2020 were used to understand trends in deaths involving gabapentinoids/Z-drugs and opioid co-involvement. These trends were studied overall and by sex, race, age, and education.</p></sec><sec id="S3"><title>Results:</title><p id="P3">Per capita overdose deaths involving gabapentinoids/Z-drugs increased almost continuously since 1999, averaging 15.8% annual growth. This rate increased to 32% in 2020, primarily due to overdoses involving synthetic opioids. Women typically had higher rates of overdose deaths involving both opioids and gabapentinoids/Z-drugs, though this disparity disappeared in 2020. White Americans and American Indians/Alaskan Natives historically had higher rates than other racial groups; however, Black Americans experienced over 60% annual growth in recent years. Low education groups have been disproportionately impacted. The age incidence tends to be older than overdoses involving opioids more generally.</p></sec><sec id="S4"><title>Conclusion:</title><p id="P4">Overdose deaths involving opioids and gabapentinoids/Z-drugs have tended to disproportionately affect women and older age groups compared to all opioid-involved overdoses. As deaths involving synthetic opioids likely reflect use of illicitly-obtained opioids, there may be less of a role for policies targeting the concurrent prescribing of gabapentinoids/Z-drugs with opioids to reduce these deaths.</p></sec></abstract><kwd-group><kwd>opioid crisis</kwd><kwd>concurrent prescriptions</kwd><kwd>fentanyl</kwd><kwd>disparities</kwd><kwd>illicit drug markets</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>